{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T13:19:46Z","timestamp":1761311986062,"version":"build-2065373602"},"reference-count":99,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) has become a widely studied subject due to its increasing prevalence and links to diseases such as type 2 diabetes and obesity. It has severe complications, including nonalcoholic steatohepatitis, cirrhosis, hepatocellular carcinoma, and portal hypertension that can lead to liver transplantation in some cases. To better prevent and treat this pathology, it is important to understand its underlying physiology. Here, we identify two main factors that play a crucial role in the pathophysiology of NAFLD: oxidative stress and the key role of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). We discuss the pathophysiology linking these factors to NAFLD pathophysiology.<\/jats:p>","DOI":"10.3390\/ijms241411271","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T01:40:02Z","timestamp":1689039602000},"page":"11271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"24","author":[{"given":"Plator","family":"Memaj","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zayd","family":"Ouzerara","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9425-3137","authenticated-orcid":false,"given":"Fran\u00e7ois R.","family":"Jornayvaz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"},{"name":"Diabetes Center, Faculty of Medicine, Geneva University, 1205 Geneva, Switzerland"},{"name":"Department of Cell Physiology and Metabolism, Faculty of Medicine, Geneva University, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Nonalcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/clinem\/dgaa575","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis","volume":"105","author":"Westerink","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1530\/JOE-13-0201","article-title":"Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance","volume":"218","author":"Asrih","year":"2013","journal-title":"J. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1542-3565(04)00014-X","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"2","author":"Younossi","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20132021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1210\/endrev\/bnz009","article-title":"Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management","volume":"41","author":"Marjot","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3748\/wjg.v25.i11.1307","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice","volume":"25","author":"Zhou","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ecl.2016.06.005","article-title":"Nonalcoholic Fatty Liver Disease","volume":"45","author":"Bril","year":"2016","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People with Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma","volume":"126","author":"Tran","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/cob.12068","article-title":"Nonalcoholic fatty liver disease in obese adults: Clinical aspects and current management strategies: Nonalcoholic fatty liver disease in obese adults","volume":"4","author":"Pallayova","year":"2014","journal-title":"Clin. Obes."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1665-2681(19)31021-X","article-title":"Transient elastography in nonalcoholic fatty liver disease","volume":"11","author":"Abenavoli","year":"2012","journal-title":"Ann. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11325-018-1625-7","article-title":"Association between obstructive sleep apnea and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"22","author":"Jin","year":"2018","journal-title":"Sleep. Breath."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.nut.2018.10.032","article-title":"Dietary patterns and nonalcoholic fatty liver disease in a Greek case\u2013control study","volume":"61","author":"Kalafati","year":"2019","journal-title":"Nutrition"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.3390\/nu7064778","article-title":"Dietary Patterns Modulate the Risk of Nonalcoholic Fatty Liver Disease in Chinese Adults","volume":"7","author":"Yang","year":"2015","journal-title":"Nutrients"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic Fatty Liver Disease 2020: The State of the Disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"204201882110555","DOI":"10.1177\/20420188211055557","article-title":"NAFLD in type 1 diabetes: Overrated or underappreciated?","volume":"12","author":"Mertens","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s10620-016-4037-1","article-title":"Quantitative Imaging Biomarkers of NAFLD","volume":"61","author":"Kinner","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"768576","DOI":"10.3389\/fphar.2021.768576","article-title":"Hepatopathy Associated with Type 1 Diabetes: Distinguishing Nonalcoholic Fatty Liver Disease from Glycogenic Hepatopathy","volume":"12","author":"Mertens","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.diabet.2012.11.002","article-title":"Nonalcoholic fatty liver disease and insulin resistance: From bench to bedside","volume":"39","author":"Gariani","year":"2013","journal-title":"Diabetes Metab."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gariani, K., and Jornayvaz, F.R. (2022). NAFLD: From Mechanisms to Therapeutic Approaches. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071747"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2015.02.018","article-title":"Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?","volume":"418","author":"Asrih","year":"2015","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Nasc\u00e8, A., Gariani, K., Jornayvaz, F.R., and Szanto, I. (2022). NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook. Antioxidants, 11.","DOI":"10.3390\/antiox11061131"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"595371","DOI":"10.3389\/fmed.2021.595371","article-title":"Oxidative Stress in Nonalcoholic Fatty Liver Disease. An Updated Mini Review","volume":"8","author":"Marciano","year":"2021","journal-title":"Front. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110785","DOI":"10.1016\/j.biopha.2020.110785","article-title":"The effect of adiponectin in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling","volume":"131","author":"Shabalala","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.cgh.2008.08.012","article-title":"Effect of Bariatric Surgery on Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis","volume":"6","author":"Mummadi","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in nonalcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/hep.28827","article-title":"Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study","volume":"64","author":"Gastaldelli","year":"2016","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., and Sabb\u00e0, C. (2022). Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients, 14.","DOI":"10.3390\/nu14214673"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1046130","DOI":"10.3389\/fendo.2022.1046130","article-title":"Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model","volume":"13","author":"Niu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/gutjnl-2011-300886","article-title":"Guidelines for liver transplantation for patients with nonalcoholic steatohepatitis","volume":"61","author":"Newsome","year":"2012","journal-title":"Gut"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"G1135-9","DOI":"10.1152\/ajpgi.2001.281.5.G1135","article-title":"Cytochrome P. -450 enzymes and oxidative stress","volume":"281","author":"Robertson","year":"2001","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/10715762.2019.1635691","article-title":"Oxidative stress biomarkers in the serum and plasma of patients with nonalcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients","volume":"53","author":"Maciejczyk","year":"2019","journal-title":"Free Radic. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1177\/147323001204000311","article-title":"Levels of the Oxidative Stress Marker \u03b3-Glutamyltranspeptidase at Different Stages of Nonalcoholic Fatty Liver Disease","volume":"40","author":"Irie","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1572-0241.2005.41500.x","article-title":"Systemic Markers of Lipid Peroxidation and Antioxidants in Patients with Nonalcoholic Fatty Liver Disease","volume":"100","author":"Yesilova","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.freeradbiomed.2004.06.033","article-title":"Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease","volume":"37","author":"Videla","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1440-1746.2011.06672.x","article-title":"Plasma reactive carbonyl species levels risk of nonalcoholic fatty liver disease: Reactive carbonyl species, NAFLD","volume":"26","author":"Liu","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0168-8278(01)00192-1","article-title":"Nonalcoholic fatty liver disease in an area of southern Italy: Main clinical, histological, and pathophysiological aspects","volume":"35","author":"Loguercio","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/ars.2009.3058","article-title":"Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities","volume":"15","author":"Gambino","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00018-006-6600-y","article-title":"Regulation of fat metabolism in the liver: Link to nonalcoholic hepatic steatosis and impact of physical exercise","volume":"63","author":"Lavoie","year":"2006","journal-title":"Cell Mol. Life Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.numecd.2008.12.015","article-title":"Hepatic lipid metabolism and nonalcoholic fatty liver disease","volume":"19","author":"Tessari","year":"2009","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/ars.2010.3848","article-title":"Adipokines and Redox Signaling: Impact on Fatty Liver Disease","volume":"15","author":"Parola","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1440-1746.2010.06253.x","article-title":"A fresh look at NASH pathogenesis. Part 1: The metabolic movers","volume":"25","author":"Larter","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2001-12927","article-title":"Etiopathogenesis of Nonalcoholic Steatohepatitis","volume":"21","author":"Chitturi","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0168-8278(02)00073-9","article-title":"In situ detection of lipid peroxidation and oxidative DNA damage in nonalcoholic fatty liver diseases","volume":"37","author":"Seki","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.mol.0000174153.53683.f2","article-title":"Nonalcoholic fatty liver disease and the metabolic syndrome","volume":"16","author":"Marchesini","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"G1339","DOI":"10.1152\/ajpgi.00509.2005","article-title":"Bax inhibition protects against free fatty acid-induced lysosomal permeabilization","volume":"290","author":"Feldstein","year":"2006","journal-title":"Am. J. Physiol. -Gastrointest. Liver Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-nutr-071811-150644","article-title":"Endoplasmic Reticulum Stress in Nonalcoholic Fatty Liver Disease","volume":"32","author":"Pagliassotti","year":"2012","journal-title":"Annu. Rev. Nutr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/livers2010003","article-title":"Oxidative Stress in Nonalcoholic Fatty Liver Disease","volume":"2","author":"Smirne","year":"2022","journal-title":"Livers"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0030-1267538","article-title":"The Role of Lipid Metabolism in the Pathogenesis of Alcoholic and Nonalcoholic Hepatic Steatosis","volume":"30","author":"Sozio","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","article-title":"Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes","volume":"11","author":"Esterbauer","year":"1991","journal-title":"Free Radic. Biol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0891-5849(89)90102-0","article-title":"Oxygen radical chemistry of polyunsaturated fatty acids","volume":"7","author":"Gardner","year":"1989","journal-title":"Free Radic. Biol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Nonalcoholic Steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1900942","DOI":"10.1002\/mnfr.201900942","article-title":"Mitochondrial Dysfunction is a Key Pathway that Links Saturated Fat Intake to the Development and Progression of NAFLD","volume":"65","author":"Meex","year":"2021","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/2047-783X-16-2-76","article-title":"Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH)","volume":"16","author":"Erhardt","year":"2011","journal-title":"Eur. J. Med. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3109\/10715762.2015.1078461","article-title":"Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Nonalcoholic fatty liver disease","volume":"49","author":"Ashraf","year":"2015","journal-title":"Free Radic. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.metabol.2017.04.011","article-title":"Nonalcoholic fatty liver disease: A sign of systemic disease","volume":"72","author":"Reccia","year":"2017","journal-title":"Metabolism"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Horst, A., Najjar, S., Wagener, C., and Tiegs, G. (2018). CEACAM1 in Liver Injury, Metabolic and Immune Regulation. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103110"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Yates, A.D., Achuthan, P., Akanni, W., Allen, J., Allen, J., Alvarez-Jarreta, J., Amode, M.R., Armean, I.M., Azov, A.G., and Bennett, R. (2019). Ensembl 2020. Nucleic Acids Res., gkz966.","DOI":"10.1093\/nar\/gkz966"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kammerer, R., and Zimmermann, W. (2010). Coevolution of activating and inhibitory receptors within mammalian carcinoembryonic antigen families. BMC Biol., 8.","DOI":"10.1186\/1741-7007-8-12"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0014-4827(86)90458-1","article-title":"Dynamic expression of the cell adhesion molecule cell-CAM 105 in fetal and regenerating rat liver","volume":"164","author":"Odin","year":"1986","journal-title":"Exp. Cell Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1074\/jbc.271.15.8809","article-title":"Cloning and Characterization of a Functional Promoter of the Rat pp120 Gene, Encoding a Substrate of the Insulin Receptor Tyrosine Kinase","volume":"271","author":"Najjar","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev-physiol-031622-043133","article-title":"Insulin Clearance in Health and Disease","volume":"85","author":"Najjar","year":"2023","journal-title":"Annu. Rev. Physiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1074\/jbc.M108415200","article-title":"Shc and CEACAM1 Interact to Regulate the Mitogenic Action of Insulin","volume":"277","author":"Poy","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"a009191","DOI":"10.1101\/cshperspect.a009191","article-title":"Insulin Receptor Signaling in Normal and Insulin-Resistant States","volume":"6","author":"Boucher","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/TACG.S171096","article-title":"IRS-1 genetic polymorphism (r.2963G>A) in type 2 diabetes mellitus patients associated with insulin resistance","volume":"11","author":"Yousef","year":"2018","journal-title":"Appl Clin Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1152\/physiol.00048.2018","article-title":"Hepatic Insulin Clearance: Mechanism and Physiology","volume":"34","author":"Najjar","year":"2019","journal-title":"Physiology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ng840","article-title":"CEACAM1 regulates insulin clearance in liver","volume":"30","author":"Poy","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1031633","DOI":"10.3389\/fendo.2022.1031633","article-title":"Nonalcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology","volume":"13","author":"Memaj","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2337\/db11-1462","article-title":"Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling","volume":"61","author":"Matveyenko","year":"2012","journal-title":"Diabetes"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/hep.26988","article-title":"Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis","volume":"59","author":"Bril","year":"2014","journal-title":"Hepatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20060499","article-title":"Insulin activates human sterol-regulatory-element-binding protein-1c (SREBP-1c) promoter through SRE motifs","volume":"400","author":"Dif","year":"2006","journal-title":"Biochem. J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tibs.2018.01.005","article-title":"SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond","volume":"43","author":"Ye","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Laurenti, M.C., Matveyenko, A., and Vella, A. (2021). Measurement of Pulsatile Insulin Secretion: Rationale and Methodology. Metabolites, 11.","DOI":"10.3390\/metabo11070409"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Rojano-Toimil, A., Rivera-Esteban, J., Manzano-Nu\u00f1ez, R., Ba\u00f1ares, J., Martinez Selva, D., Gabriel-Medina, P., Ferrer, R., Peric\u00e0s, J.M., and Ciudin, A. (2022). When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes, NAFLD. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123286"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/dme.12805","article-title":"Type 1 Diabetes Is Not Associated with an Increased Prevalence of Hepatic Steatosis","volume":"32","author":"Petit","year":"2015","journal-title":"Diabet. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejim.2022.03.025","article-title":"Non-Alcoholic Fatty Liver Disease: Identical Etiologic Factors in Patients with Type 1 and Type 2 Diabetes","volume":"100","author":"Westerink","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cmet.2005.06.001","article-title":"Insulin acutely decreases hepatic fatty acid synthase activity","volume":"2","author":"Najjar","year":"2005","journal-title":"Cell Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11154-021-09708-3","article-title":"Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review","volume":"23","author":"Camastra","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8121","DOI":"10.1074\/jbc.M116.714014","article-title":"PPAR\u03b1 (Peroxisome Proliferator-activated Receptor \u03b1) Activation Reduces Hepatic CEACAM1 Protein Expression to Regulate Fatty Acid Oxidation during Fasting-refeeding Transition","volume":"291","author":"Ramakrishnan","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1023\/B:PHAM.0000041444.06122.8d","article-title":"Peroxisome Proliferator-Activated Receptor (PPAR): A Pharmacological Target with a Promising Future","volume":"21","author":"Li","year":"2004","journal-title":"Pharm. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep4.1117","article-title":"Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis","volume":"2","author":"Ghadieh","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.2337\/db09-1253","article-title":"Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes","volume":"59","author":"Salehi","year":"2010","journal-title":"Diabetes"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/ars.2016.6776","article-title":"Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis","volume":"26","author":"Schohraya","year":"2017","journal-title":"Antioxid. Redox Signal."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:09:45Z","timestamp":1760126985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":99,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411271"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411271","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,7,10]]}}}